Brivaracetam as add‐on treatment in focal epilepsy: A real‐world time‐based analysis

The study assessed the clinical response to add‐on brivaracetam (BRV) in real‐world practice by means of time‐to‐baseline seizure count methodology. Patients with focal epilepsy who were prescribed add‐on BRV were identified. Primary endpoint was the time‐to‐baseline seizure count defined as the num...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Epilepsia (Copenhagen) 2021-01, Vol.62 (1), p.e1-e6
Hauptverfasser: Lattanzi, Simona, De Maria, Giovanni, Rosati, Eleonora, Didato, Giuseppe, Chiesa, Valentina, Ranzato, Federica, Canafoglia, Laura, Cesnik, Edward, Anzellotti, Francesca, Meletti, Stefano, Pauletto, Giada, Nilo, Annacarmen, Bartolini, Emanuele, Marino, Daniela, Tartara, Elena, Luisi, Concetta, Bonanni, Paolo, Marrelli, Alfonso, Stokelj, David, Dainese, Filippo, Foschi, Nicoletta, Cagnetti, Claudia, Gazzina, Stefano, Contento, Margherita, Biggi, Martina, Magliani, Matteo, Di Giacomo, Roberta, Pastori, Chiara, Canevini, Maria Paola, Zambrelli, Elena, Billo, Giuseppe, Casazza, Marina, Fallica, Elisa, Rosa, Giuseppa, Dono, Fedele, Speranza, Rino, Cioclu, Cristina, Vaudano, Anna Elisabetta, Kiferle, Lorenzo, Galli, Rosita, Guadagni, Martina, Galimberti, Carlo Andrea, Kassabian, Benedetta, Ferreri, Florinda, Osanni, Elisa, Ciuffini, Roberta, Badioni, Valeria, Beretta, Simone
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The study assessed the clinical response to add‐on brivaracetam (BRV) in real‐world practice by means of time‐to‐baseline seizure count methodology. Patients with focal epilepsy who were prescribed add‐on BRV were identified. Primary endpoint was the time‐to‐baseline seizure count defined as the number of days until each patient experienced the number of focal seizures that occurred in the 90 days before BRV initiation. Subgroup analysis was performed according to levetiracetam (LEV) status (naive vs prior use). Three‐hundred eighty‐seven patients were included. The overall median time‐to‐baseline seizure count was 150 (95% confidence interval [CI] = 130‐175) days. The median time‐to‐baseline seizure count was 198 (lower limit of 95% CI = 168) days for LEV‐naive patients, 126 (95% CI = 105‐150) days for patients with prior LEV use and withdrawal due to insufficient efficacy, and 170 (95% CI = 128‐291) days for patients who discontinued LEV due to adverse events (P = .002). The number of prior antiseizure medications (adjusted hazard ratio [adjHR] = 1.07, 95% CI = 1.02‐1.13, P = .009) and baseline monthly seizure frequency (adjHR = 1.004, 95% CI = 1.001‐1.008, P = .028) were independently associated with the primary endpoint. Add‐on BRV improved seizure control in LEV‐naive and LEV‐prior patients. The time‐to‐baseline seizure count represents an informative endpoint alongside traditional study outcomes and designs.
ISSN:0013-9580
1528-1167
DOI:10.1111/epi.16769